Type 2 MI a legitimate efficacy endpoint in cardiovascular trials? A critical appraisal

Saved in:

Bibliographic Details
Main Authors:	F. H. van Bruggen, H. J. Luijendijk
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2025-06-01
Series:	Frontiers in Cardiovascular Medicine
Subjects:	type 2 MI PCSK 9 inhibitors GLP 1 analog SLGT inhibitors efficacy outcomes safety outcomes
Online Access:	https://www.frontiersin.org/articles/10.3389/fcvm.2025.1564432/full
Tags:	Add Tag No Tags, Be the first to tag this record!

Internet